Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphery. Cons...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Neuroinflammation
Päätekijät: Simon, Micha, Ipek, Rojda, Homola, György A., Rovituso, Damiano M., Schampel, Andrea, Kleinschnitz, Christoph, Kuerten, Stefanie
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6086993/
https://ncbi.nlm.nih.gov/pubmed/30098594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-018-1263-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia